Insurance Formularies Block Lower-Emission Inhalers

Commercial insurance formularies have presented a significant barrier to the adoption of lower-emission inhalers for patients with asthma and chronic obstructive pulmonary disease (COPD), according to a study published in the Journal of the American Medical Association (JAMA) Network Open on March 18, 2024. These formularies, which are lists of prescription drugs covered by an insurance plan, often do not adequately favor or include the newer, environmentally friendlier inhaler options, thereby limiting patient and physician access. The study analyzed prescription data and formulary policies, finding that the continued reliance on older metered-dose inhalers (MDIs) is largely driven by these insurance coverage decisions. MDIs, while effective for respiratory conditions, utilize propellants that contribute to greenhouse gas emissions, specifically hydrofluorocarbons (HFCs), which have a high global warming potential. In contrast, newer inhaler technologies, such as dry powder inhalers (DPIs) and breath-actuated MDIs, use propellants with significantly lower or zero global warming potential, or deliver medication without propellants altogether. The research highlights that despite the availability of these greener alternatives, insurance plans frequently place the higher-emission MDIs in preferred or lower-tier cost categories, making them more accessible and affordable for patients. This formulary design inadvertently encourages the continued use of older inhalers, undermining efforts to reduce the healthcare sector's carbon footprint. The environmental impact of MDIs is substantial, with estimates suggesting that the annual emissions from MDIs used in the UK alone are equivalent to the carbon emissions from approximately 15,000 cars. Similar patterns are observed in other developed nations. The study's authors recommend that insurance companies and pharmacy benefit managers revise their formulary strategies to incentivize the use of low-emission inhalers. This could involve placing lower-emission inhalers in preferred tiers, offering co-pay assistance for these alternatives, or actively educating physicians and patients about the environmental benefits and comparable efficacy of newer devices. Such changes are crucial for aligning healthcare practices with broader climate action goals. The findings underscore a critical intersection between public health, environmental sustainability, and healthcare policy, indicating that policy interventions are necessary to facilitate the transition to more sustainable medical treatments. The study's methodology involved a retrospective analysis of prescription claims data and a review of formulary documents from major commercial health insurance plans in the United States. The researchers identified specific inhaler types and their associated greenhouse gas emission profiles, correlating this with their placement on insurance formularies and subsequent prescription patterns. The implications extend beyond environmental concerns, as the study also touches upon the potential for cost savings associated with some of the newer inhaler technologies, although formulary design remains the primary driver of current prescribing habits. The transition to lower-emission inhalers is a key recommendation from environmental health organizations and respiratory societies aiming to reduce the significant carbon footprint of the pharmaceutical industry and healthcare systems globally. This study provides concrete evidence of the systemic barriers that need to be addressed to achieve these sustainability targets in respiratory care.